剪接因子1N端1-320氨基酸片段的原核表达及纯化

目的:通过扩增剪接因子1(SF1)的N端1-320氨基酸(aa)片段对应的cDNA,构建His融合蛋白原核表达质粒pET-28a(+)/SF1(1-320aa),在大肠杆菌中诱导表达并进行亲和纯化。方法:PCR扩增SF1的1-320 aa片段对应的cDNA,扩增产物和载体pET-28a(+)经酶切回收,连接载体和目的片段,获得重组质粒,转化大肠杆菌DH5α,挑取克隆、酶切鉴定、测序,将测序正确的重组质粒转化大肠杆菌BL21(DE3),IPTG诱导表达,SDS-PAGE和West-ern印迹分析蛋白表达情况,亲和纯化His-SF1(1-320aa)。结果:SF1片段以正确的读框插入pET-28a(+),IPTG可以诱导大肠杆菌表达重组蛋白,SDS-PAGE和Western印迹证实得到相对分子质量约为40×103的蛋白,亲和纯化得到高纯度蛋白质。结论:构建了His融合蛋白原核表达质粒pET-28a(+)/SF1(1-320aa),并获得His-SF1(1-320aa)融合蛋白,为进一步研究SF1和U2AF65之间的相互作用及对剪接体形成的影响提供了基础。     

人FGF21原核表达载体的构建及重组蛋白表达

构建人FGF21(fibroblast growth factor,FGF)cDNA的原核表达载体并诱导其重组蛋白表达。提取人肝脏总RNA后,经RT-PCR扩增获得目的片段,构建其T载体进行保存。再构建重组原核表达载体pET-28a(+)-h FGF21,重组质粒转化至大肠杆菌菌株BL21(DE3)中,在IPTG诱导下得到可溶性表达,采用亲和层析法纯化表达产物后,进行Western blot鉴定。成功构建重组质粒pET-28(+)-hFGF21,对其进行可溶性表达后成功纯化出his-hFGF21,经Western blot鉴定该融合蛋白可与FGF21抗体特异性结合。成功构建pET-28(+)-hFGF21,并可溶性表达his-hFGF21蛋白。     

植原体免疫主导膜蛋白Imp基因原核表达载体构建及表达

旨在构建植原体免疫主导膜蛋白Imp基因原核表达载体,并进行初步表达。以重组克隆质粒pMD18-T-Imp为模板,PCR扩增Imp基因片段。构建表达载体pET-28a(+)-Imp,转化宿主菌E.coliBL21(DE3)。筛选阳性克隆,提取重组质粒作PCR鉴定、酶切鉴定及IPTG诱导表达鉴定。PCR及双酶切结果显示,重组质粒pET-28a(+)-Imp构建成功。经IPTG诱导BL21(pET-28a(+)-Imp)表达约20 kD的蛋白,与预期的携带6×His-Tag的目的蛋白(19.5 kD)大小相符,主要以包涵体形式存在。结果显示,构建的表达载体pET-28a(+)-Imp在E.coliBL21(DE3)中能够达一定量表达,为进一步纯化Imp蛋白奠定基础。     

家蚕蚕丝蛋白轻链基因克隆及原核表达研究

克隆家蚕丝素蛋白轻链基因并构建原核表达系统。以家蚕总RNA反转录cDNA为模板,利用特异性引物FiblF和FiblR扩增编码丝素蛋白轻链基因(Fibl)765bp片段,以pET-28a(+)构建pET-28a(+)-Fibl表达载体,将重组表达载体转化BL21(DE3)感受态细胞构建产丝素蛋白轻链(Fibl)蛋白工程菌。构建了原核表达载体pET-28a(+)-Fibl,经测序验证基因序列正确,经聚丙烯酰胺凝胶电泳和Western Blot初步判断出表达产物为35.3KD的丝素蛋白轻链蛋白。成功构建产丝素蛋白轻链蛋白的工程菌BL21-pET-28a(+)-Fibl,为丝素蛋白的原核表达研究奠定了基础。     

肠出血性大肠杆菌毒力因子Z1444的原核表达及其丝/苏氨酸激酶活性验证

目的:在大肠杆菌中表达肠出血性大肠杆菌(EHEC)毒力岛上的毒力因子Z1444并纯化,对其丝/苏氨酸激酶活性进行初步检测。方法:根据GenBank中Z1444基因序列及pET-28a(+)载体的多克隆位点设计引物,以EHECO157∶H7全菌裂解液为模板,经PCR钓取1047 bp的目的片段,与表达载体pET-28a(+)连接,构建重组表达质粒pET-28a(+)-Z1444,将其转化至大肠杆菌BL21(DE3)中,IPTG诱导蛋白表达并经SDS-PAGE鉴定,利用体外反应体系鉴定重组蛋白的丝/苏氨酸激酶活性。结果:双酶切和测序鉴定表明,pET-28a(+)-Z1444原核表达质粒构建正确;诱导表达后经纯化,获得纯度在90%以上的可溶性重组Z1444,相对分子量约为38×103;体外酶活实验验证了Z1444的丝/苏氨酸激酶活性。结论:Z1444在大肠杆菌中获得高效可溶性表达,为后续功能验证奠定了基础。     

人巨细胞病毒编码蛋白pUL23在E.coli BL21(DE3)中的表达和纯化

大肠杆菌中高效表达携带组氨酸标签的人巨细胞病毒皮层蛋白pUL23,并进行纯化以及鉴定.提取感染HCMV Towne病毒株的HFF细胞的总RNA,逆转录为cDNA作为模板,经PCR获得UL23的基因片段,将此片段插入表达载体pET-28a(+),构建pET28a(+)-UL23重组质粒.将pET28a(+)-UL23转化至大肠杆菌BL21( DE3),进行IPTG诱导表达.表达产物经Western blotting分析后进行发酵,再用Ni sepharose亲和层析纯化,纯化产物进行SDS-PAGE和Western blotting检测.结果表明,成功构建pET28a(+)-UL23原核表达载体,表达及纯化了His-pUL23融合蛋白.为进一步研究pUL23奠定基础.     

Nono蛋白的原核表达、纯化和多克隆抗体的制备

目的表达和纯化带多聚组氨酸（6×His）标签的Nono （ non-POU-domain-containing, octamer-binding protein ）融合蛋白并制备抗Nono多克隆抗体。方法构建pET-28a（＋）-Nono重组表达质粒,转入Rosetta（DE3）大肠埃希菌,以IPTG诱导6×His-Nono融合蛋白表达,经镍离子金属螯合树脂纯化后,用纯化出的蛋白免疫BALB／C小鼠制备多克隆抗体,并用ELISA检测多克隆抗体的效价,Western印迹检测多克隆抗体的特异性。结果在大肠埃希菌中诱导出高水平表达的His-Nono融合蛋白,经亲和树脂纯化后免疫小鼠,获得了高特异性的抗Nono抗血清。结论成功构建pET-28a（＋）-Nono原核表达质粒,表达并纯化出高纯度的目标蛋白,制备出高滴度、高特异性的多克隆抗体。     

δ-睡眠肽与GFP融合蛋白的表达和纯化

构建δ-睡眠肽(DSIP)蛋白与GFP的融合基因表达载体,高效表达和纯化GFP-DSIP融合蛋白。通过SOE-PCR拼接DSIP全长编码基因,并使得DSIP上游具有肠激酶识别位点,经双酶切定向克隆至表达载体pET-28a,构建重组载体pET-28a-DSIP,通过PCR扩增GFP全长编码基因,经双酶切定向克隆至pET-28a-DSIP,构建原核重组表达载体pET-28a-GFP-DSIP,通过双酶切和测序鉴定后,导入E.coli BL21宿主菌中,IPTG诱导表达融合蛋白,采用镍亲和层析和分子筛凝胶层析获得高纯度蛋白,SDS-PAGE分析鉴定。经测序鉴定成功构建了原核重组表达载体pET-28a-GFP-DSIP,在IPTG诱导下获得可溶性的绿色荧光蛋白与睡眠肽的融合蛋白,经Ni-NTA亲和层析纯化成功获得高纯度的融合蛋白。成功构建了DSIP与GFP融合基因的重组表达载体,确定了GFP-DSIP融合蛋白诱导表达的最佳条件,获得了较高纯度的融合蛋白,为进一步研究DSIP蛋白的生物学功能奠定了基础。     

人抗酶抑制因子-1的克隆与原核表达

目的:克隆人抗酶抑制因子-1(ornithine decarboxylase antizyme inhibitor-1,OAZI-1)cDNA,建立在大肠杆菌中原核表达并纯化人OAZI-1蛋白的实验技术。方法:巢式RT-PCR法从人A549总RNA中扩增人OAZI-1 cDNA并构建pET-28a/OAZI-1原核表达质粒。该质粒转化大肠杆菌原核表达菌BL21(DE3)后IPTG诱导表达。诱导表达出的重组蛋白用Ni-NTA树脂亲和层析纯化。SDS-PAGE和Western法检测重组OAZI-1蛋白的表达和纯化。结果:成功克隆出编码全长人OAZI-1的cDNA序列,并构建出原核表达质粒pET-28a/OAZI-1。DNA测序分析,重组质粒中的OAZI-1 cDNA无突变,与6×His标签框架对接正确。重组质粒转化入大肠杆菌表达菌BL21(DE3)中后,可用IPTG诱导表达出重组OAZI-1蛋白,该重组蛋白可用Ni-NTA树脂亲和层析纯化。结论:成功建立了人抗酶抑制因子的原核表达和纯化的实验方法,为后续OAZI-1的功能研究奠定了基础。     

小鼠beta防御素2原核表达与抗菌作用的初步研究

构建小鼠β-防御素-2( mouse beta defensins 2,mBD2)原核表达质粒pET32/mBD2,进行蛋白诱导表达及纯化,测定并纯化蛋白的抗菌活性.旨在为选一步研究其生物学特性奠定基础.通过腹腔注射脂多糖(lipopoly-saccharide,LPS)建立小鼠急性时相反应,采用RT-PCR方法扩增mBD2成熟肽,经KpnⅠ和XhoⅠ双酶切后插入相同酶切的pET-32a(+)载体,构建的重组质粒.将鉴定正确的重组质粒转化大肠杆菌表达菌株BL21 (DE3),采用异丙基-D-硫代半乳糖苷(IPTG)诱导融合蛋白的表达.通过镍亲和层析获得纯化的融合蛋白.将融合蛋白采用肠激酶酶切、洗脱并用滤纸片法测定目的蛋白的抗菌活性.成功构建了原核表达质粒pET32a(+)/mBD2,并转化工程菌BL21( DE3).在0.25 mmol/L IPTG、30℃诱导4h条件下获得的融合蛋白.采用抑菌试验证实蛋白具有一定的抑制革兰阳性菌及阴性菌生长的作用.本研究成功构建了pET32/mBD2原核表达质粒,得到了在大肠杆菌中稳定表达mBD2蛋白.     

Csnk1a1 inhibition modulates the inflammatory secretome and enhances response to radiotherapy in glioma

Glioblastoma multiforme (GBM), a fatal brain tumour with no available targeted therapies, has a poor prognosis. At present, radiotherapy is one of the main methods to treat glioma, but it leads to an obvious increase in inflammatory factors in the tumour microenvironment, especially IL-6 and CXCL1, which plays a role in tumour to resistance radiotherapy and tumorigenesis. Casein kinase 1 alpha 1 (CK1α) (encoded on chromosome 5q by Csnk1a1) is considered an attractive target for Tp53 wild-type acute myeloid leukaemia (AML) treatment. In this study, we evaluated the anti-tumour effect of Csnk1a1 suppression in GBM cells in vitro and in vivo. We found that down-regulation of Csnk1a1 or inhibition by D4476, a Csnk1a1 inhibitor, reduced GBM cell proliferation efficiently in both Tp53 wild-type and Tp53-mutant GBM cells. On the contrary, overexpression of Csnk1a1 promoted cell proliferation and colony formation. Csnk1a1 inhibition improved the sensitivity to radiotherapy. Furthermore, down-regulation of Csnk1a1 reduced the production and secretion of pro-inflammatory factors. In the preclinical GBM model, treatment with D4476 significantly inhibited the increase in pro-inflammatory factors caused by radiotherapy and improved radiotherapy sensitivity, thus inhibiting tumour growth and prolonging animal survival time. These results suggest targeting Csnk1a1 exert an anti-tumour role as an inhibitor of inflammatory factors, providing a new strategy for the treatment of glioma.     

扩增和纯化携带肌浆网钙ATP酶重组腺病毒的实验方法

目的:通过扩增和纯化rAd.SERCA2a,为转SERCA2a基因研究提供实验基础,并为建立基因库提供稳定可靠的实验方法.方法:用100μL 1.9×10<'12>pfu/ml rAd.SERCA2a感染HEK293细胞,出现细胞病变效应时收获细胞,经物理反复冻融方法及两步氯化铯超速离心方法获得纯化的rAd.SERCA2a,紫外分光光度计比色法测定病毒DNA质粒数.结果:rAd.SERCA2a成功在HEK293细胞表达呈现绿色荧光,纯化的rAd-SERCA2a-GFP DNA质粒数为1.3±0.58×10<'12>pfu/mL,OD<,260>/OD<,280>比值为1.57±0.49(n=50).结论:建立了稳定可靠的借助HEK293细胞培养扩增rAd.SERCA2a的实验方法,纯化后的高效价的SERCA2a基因的重组腺病毒可直接用于心力衰竭的实验研究,对重组腺病毒携带其他基因的扩增与提纯方法也具有一定的参考价值.     

A model for signaling specificity of Wnt/Frizzled combinations through co-receptor recruitment

Wnts control mammalian developmental morphogenesis and are critical for adult stem cell maintenance. Wnts initiate several intracellular signaling cascades, such as Wnt/β-catenin-, Wnt/Ca²⁺- and Wnt/ROR2-signaling. Signaling preference of Wnts for these various pathways is thought to depend on the repertoire of receptors present on recipient cells. Here, we propose a further refinement of this receptor model and hypothesize that Wnt signaling specificity depends on co-receptor recruitment upon binding of Wnt to Frizzled receptor molecules. In this model, recruitment of LRP5/6 leads to activation of Wnt/β-catenin signaling, whereas signaling through other pathways is mediated by recruiting ROR2.     

mir-34a在神经元中的表达特征及功能研究

本研究采用Northern Blotting、ISH／FISH等手段首次发现mir-34a在恒河猴大脑神经元中呈年龄梯度表达的规律。同时我们发现mir-34a在大鼠前额叶原代培养神经元中的表达亦呈随培养时程增加而递增的趋势。进一步研究表明,过表达mir-34a可能通过抑制BCL-2而引起神经元凋亡。我们的研究结果提示mir-34a可能在神经元的发育与衰老机制中起着重要作用。     

肝郁脾虚证模型大鼠血流变及TXB2、PGF1a的变化

目的:探查中医肝郁脾虚证模型的血流变及相关调节因子的状态。方法:采用慢性束缚应激 过度疲劳 饮食失节法建立大鼠肝郁脾虚证模型,测定大鼠造模三周、自然恢复一周时的血流变和血浆TXB2、PGF1a。结果:与正常组相比,模型组大鼠造模三周150/s、38/s、10/s、5/s切变率下的全血粘度和还原粘度均显著升高(P＜0．001),红细胞聚集指数显著降低(P＜0．001),红细胞压积显著升高(P＜0．01),红细胞变形指数无显著性差异(P＞0．05);血浆TXB2显著升高(P＜0．001),6-keto-PGF1a显著降低(P＜0．05), TXB2/PGF1a显著升高(P＜0．01);模型组大鼠第四周150/s、38/s、10/s、5/s切变率下的全血粘度和还原粘度仍显著升高(P＜0．001或P＜0．01);红细胞聚集指数显著降低(P＜0．001);红细胞压积与变形指数无显著性差异(P＞0．05);血浆TXB2和TXB2/PGF1a显著降低(P＜0．05),6-keto-PGF1a显著升高(P＜0．05)。结论:肝郁脾虚证大鼠存在血液高粘和血栓易形成状态,恢复期血液高粘同时伴有扩血管因素的加强。提示肝郁脾虚证有血流变的异常和血浆TXA2-PGI2的平衡失调,主要涉及到血小板和血浆因素的参与。     

Embryogenic staging of fugu, Takifugu rubripes, and expression profiles of aldh1a2, aldh1a3 and cyp26a1

Fugu (Takifugu rubripes) has contributed as an ideal model organism for understanding the structure and evolution of vertebrate genomes, but also has potential as a good model organism for developmental biology because of the availability of the genome information. However, there is no comprehensive report describing the developmental stages, which is fundamental data for developmental biology. Here we describe a series of stages of the embryonic development of fugu during the first 8 days after fertilization, i.e. from fertilization to hatching. We define seven periods of embryogenesis – the zygote, cleavage, blastula, gastrula, segmentation, pharyngula, and hatching periods. Stages subdividing these periods are defined based on morphological characteristics. In addition, as a model experiment of gene expression analysis using this staging series, we performed in situ hybridization of aldh1a2, aldh1a3 and cyp26a1 that play regulatory roles in retinoic acid (RA) metabolism essential for embryogenesis. This report provides fundamental information on fugu embryogenesis, which is anticipated to facilitate the use of fugu as a model organism for developmental studies.     

Low dose Oral Interferon Alpha 2a in HIV-1 Seropositive Patients: A Double-blind, Placebo-controlled Trial

Low dose oral interferon alpha has been shown to be of benefit in viral disease in animals. In a double-blind, placebo-controlled trial, 177 patients seropositive for HIV-1 were randomly assigned to receive placebo or recombinant human interferon alpha 2a (rIFN). Endpoints were survival, alteration of disease classification, performance, and changes in CD4+ T cell numbers. There was a trend for improved survival in the group receiving rIFN at the dose of 1.0 IU/lb. The changes in disease classification or in weight were not significantly different. Performance was improved to a greater extent (p=0.1) in the patients who received the two higher rIFN dosages (1.0 IU/lb and 10.0 IU/lb) at 6 months. In addition, the CD4+ T cell count was improved only in the 1.0 IU/lb dose treatment group at 6 months. Treatment with low dose oral interferon at 1.0 IU/lb was associated with improved CD4+ T cell count, performance and a trend toward enhanced survival in HIV seropositive patients. These differences were, however, not statistically significant. A larger study, with better return rate, will be needed to determine whether low dose, oral interferon alpha is actually beneficial for these patients.     

Constitutive overexpression of the integral membrane protein Itm2A enhances myogenic differentiation of C2C12 cells

Integral membrane protein 2A (Itm2A) is a transmembrane protein belonging to a family composed of at least two other members, Itm2B and Itm2C, all of them having a different expression pattern. The protein serves as a marker for early stages in chondrogenesis and T-cell development. Itm2A is also highly expressed in skeletal muscle. In order to understand the role of Itm2A in muscle development, we constitutively overexpressed exogenous Itm2A in C2C12 myoblast cells. Several clones expressing high levels of Itm2a were isolated and characterized. Overexpression was associated with enhanced tube formation and the appearance of multinuclear cells. Gene expression analysis demonstrated that muscle creatin kinase was upregulated in the presence of exogenous Itm2A. Interestingly, proliferation rates were not altered in the undifferentiated myoblast C2C12 cells. These results demonstrate that overexpression of Itm2a in C2C12 enhances myogenic differentiation in vitro.     

Differential expression of foxl2 and cyp19a1a mRNA during gonad developmental stages in great sturgeon Huso huso

This study aimed to determine the sex specificity and expression pattern of foxl2 and cyp19a1a genes in great sturgeon Huso huso gonads during gonadal sex differentiation and development. The results revealed that foxl2 and cyp19a1a mainly expressed in female gonads and during gonad development the foxl2 and cyp19a1a mRNA expression is required for ovarian development.